Study to Assess the Long-term Safety, Tolerability, Efficacy of Secukinumab in Pediatric Patients of Age 6 to <18 Years, With Moderate to Severe Plaque Psoriasis



Status:Recruiting
Conditions:Psoriasis
Therapuetic Areas:Dermatology / Plastic Surgery
Healthy:No
Age Range:6 - 17
Updated:3/29/2019
Start Date:August 29, 2018
End Date:September 15, 2023
Contact:Novartis Pharmaceuticals
Email:novartis.email@novartis.com
Phone:1-888-669-6682

Use our guide to learn which trials are right for you!

A Randomized, Open-label, Multicenter Trial to Assess the Efficacy of Subcutaneous Secukinumab after12 Weeks of Treatment, and to Assess the Long-term Safety, Tolerability, Efficacy in Subjects From 6 to <18 Years of Age With Moderate to Severe Chronic Plaque Psoriasis

This is an open-label, parallel-group, two-arm, multicenter study in pediatric subjects aged
6 years to less than 18 years, at randomization, with moderate to severe chronic plaque
psoriasis. Approximately 80 subjects (at least 60 subjects with moderate severity) will be
enrolled. subjects will be stratified by weight. It is expected that subjects will be
enrolled in about 40 centers worldwide.


Inclusion Criteria:

1. Written informed assent and parental permission (age as per local law) obtained at
screening before any assessment is performed.

2. Must be 6 to less than 18 years of age at the time of randomization

3. Moderate to Severe plaque psoriasis, defined as a PASI score ≥ 12, and IGA mod 2011
score of ≥ 3, and BSA involvement of ≥10%, at randomization.

4. Subject being regarded by the investigator to be a candidate for systemic therapy.

Exclusion Criteria:

1. Forms of psoriasis other than chronic plaque-type active at randomization

2. Drug-induced psoriasis

3. Ongoing use of prohibited treatments

4. Female subjects of childbearing potential defined as all women physiologically capable
of becoming pregnant, unless they are using effective methods of contraception during
dosing and for 16 weeks after stopping study treatment

5. Pregnant or nursing (lactating) females

6. Subjects with total WBC count <2,500/μL, or platelets <100,000/μL or neutrophils
<1,500/μL or hemoglobin <8.5 g/dL at screening

7. Previous exposure to secukinumab or any other biologic drug directly targeting IL-17
or the IL-17 receptor
We found this trial at
8
sites
?
mi
from
Bruxelles,
Click here to add this to my saved trials
California City, California 93405
?
mi
from
California City, CA
Click here to add this to my saved trials
Jacksonville, Florida 32216
?
mi
from
Jacksonville, FL
Click here to add this to my saved trials
Lebanon, New Hampshire 03756
?
mi
from
Lebanon, NH
Click here to add this to my saved trials
Miami, Florida 33136
?
mi
from
Miami, FL
Click here to add this to my saved trials
Norfolk, Virginia 23507
?
mi
from
Norfolk, VA
Click here to add this to my saved trials
Pflugerville, Texas 78660
?
mi
from
Pflugerville, TX
Click here to add this to my saved trials
San Antonio, Texas 78207
Novartis Novartis, which was created in 1996 by the merger of the Swiss companies Ciba-Geigy...
?
mi
from
San Antonio, TX
Click here to add this to my saved trials